Harvard Bioscience (HBIO) Liabilities and Shareholders Equity (2010 - 2026)

Harvard Bioscience (HBIO) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $77.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 2.33% year-over-year to $77.9 million; the TTM figure through Mar 2026 stood at $316.1 million (down 32.26% YoY), while the FY2025 annual figure was $80.1 million, down 36.77% from the prior year.
• Liabilities and Shareholders Equity declined to $77.9 million in Q1 2026 per HBIO's latest filing, from $80.1 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $158.0 million in Q1 2022 and bottomed at $77.9 million in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $122.8 million across 5 years, with a median of $133.2 million in 2024.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity increased 4.49% — and 2025, when it tumbled 40.57%.
• Harvard Bioscience's Liabilities and Shareholders Equity stood at $145.4 million in 2022, then slipped by 5.5% to $137.4 million in 2023, then decreased by 7.81% to $126.6 million in 2024, then slumped by 36.77% to $80.1 million in 2025, then slipped by 2.66% to $77.9 million in 2026.
• Business Quant data shows HBIO's Liabilities and Shareholders Equity at $77.9 million in Q1 2026, $80.1 million in Q4 2025, and $78.0 million in Q3 2025.